drugset
drugset / Trial / NCT05853172

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

NCT05853172 ↗

Phase 2 Unknown 30 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, open-label，single-center, phase II study, aiming to to evaluate the surgical conversion feasibility of AK104 combined with apatinib, paclitaxel and S-1 in unresectable stage IV G/GEJ cancer.

Timeline

Start
2023-03-21
Primary completion
2025-03-21
Completion
2025-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 10 mg/kg Intravenous
Subject Paclitaxel Small molecule 40 mg/m2 Intravenous
Subject Paclitaxel Small molecule 90 mg/m2 Intravenous
Subject Paclitaxel Small molecule 130 mg/m2 Intravenous
Subject Rivoceranib Small molecule 250 mg Oral
Subject S-1 Small molecule 60 mg Oral

Indications

gastric cancer